OpGen - OPGN Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPGN shares.
View OPGN analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month price objectives for OpGen's stock. Their OPGN share price forecasts range from $1.25 to $3.00. On average, they predict the company's stock price to reach $2.13 in the next twelve months. This suggests a possible upside of 642.5% from the stock's current price.
View analysts price targets for OPGN or view top-rated stocks among Wall Street analysts.

OpGen's stock was trading at $1.00 at the start of the year. Since then, OPGN stock has decreased by 71.4% and is now trading at $0.2862.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our OPGN earnings forecast.

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, August, 11th. The medical research company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. The medical research company had revenue of $0.97 million for the quarter, compared to analyst estimates of $1 million. OpGen had a negative trailing twelve-month return on equity of 75.61% and a negative net margin of 624.26%.

OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

OpGen issued an update on its second quarter 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.00 million-$1.00 million, compared to the consensus revenue estimate of $950.00K.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPGN stock can currently be purchased for approximately $0.29.

OpGen (NASDAQ:OPGN) has a market capitalization of $13.83 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for the company is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.